Zioptan®
Tafluprost 0.0015% · preservative-free ophthalmic solution
Antiglaucoma
Approved uses
Open-angle glaucoma or ocular hypertension
One drop in the conjunctival sac of the affected eye(s) once daily in the evening; not to exceed once daily.
Lowers IOP from about 25 mmHg to about 18 mmHg, matching timolol at every time point.
Open-angle glaucoma or ocular hypertension in patients with ocular surface signs or symptoms on preserved latanoprost
One drop once daily in the evening, substituted directly for the preserved prostaglandin with no washout in the study.
IOP holds steady after switching from preserved latanoprost while surface signs and symptoms roughly halve.
Contraindications
None.
0.0015% (0.015 mg/mL) preservative-free ophthalmic solution, 0.3 mL single-use containers, cartons of 30 and 90, 10 containers per foil pouch
Fluorinated prostaglandin F2alpha analog given as an ester prodrug that is hydrolyzed in the eye to tafluprost acid, a selective FP prostanoid receptor agonist believed to lower IOP by increasing uveoscleral outflow; the exact mechanism is unknown. IOP reduction starts approximately 2 to 4 hours after the first dose, with the maximum effect reached after 12 hours.
Warnings & Precautions
- Pigmentation: Tafluprost has been reported to cause increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes, which is expected to increase as long as it is administered. After discontinuation, iris pigmentation is likely to be permanent, while periorbital pigmentation and eyelash changes have been reported to be reversible in some patients. Inform patients of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known.
- Iris color change: May not be noticeable for several months to years. Brown pigmentation around the pupil typically spreads concentrically toward the periphery, from increased melanin content in the melanocytes rather than more melanocytes, and nevi and freckles of the iris do not appear to be affected. Treatment can be continued in patients who develop noticeably increased iris pigmentation, but these patients should be examined regularly.
- Eyelash changes: May gradually change eyelashes and vellus hair in the treated eye, including increased length, color, thickness, shape and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.
- Intraocular inflammation: Caution with active intraocular inflammation such as iritis or uveitis, which may be exacerbated.
- Macular edema: Macular edema including cystoid macular edema has been reported with prostaglandin F2alpha analogs; caution in aphakia, in pseudophakia with a torn posterior lens capsule, and with other known risk factors.
- Single-use container sterility: Sterility cannot be maintained once a unit is opened; use it immediately for one or both eyes and discard the remaining contents.
Common Side Effects
- Ocular, most common: conjunctival hyperemia, range 4% to 20% (905 patients across five controlled studies of up to 24 months, pooling preservative-containing and preservative-free tafluprost; about 1% discontinued for ocular reactions).
- Ocular, 2% or more: ocular stinging or irritation 7%, ocular pruritus including allergic conjunctivitis 5%, cataract 3%, dry eye 3%, ocular pain 3%, eyelash darkening 2%, growth of eyelashes 2%, blurred vision 2%.
- Ocular, postmarketing: iritis and uveitis; periorbital and lid changes including deepening of the eyelid sulcus, observed with prostaglandin analogs as a class.
- Systemic, 2% to 6%: headache 6%, common cold 4%, cough 3%, urinary tract infection 2%.
- Systemic, postmarketing: exacerbation of asthma, dyspnea.
Pregnancy: Category C. IV tafluprost was teratogenic in rats and rabbits, increasing post-implantation loss in both, reducing fetal body weight and increasing vertebral skeletal abnormalities in rats, and causing skull, brain, and spine malformations in rabbits; rabbit effects occurred at about 5 times the maximum clinical exposure by Cmax, while rats showed no embryo-fetal effects at 343 times. No adequate and well-controlled studies in pregnant women, so use only if the potential benefit justifies the potential fetal risk, with adequate contraception in women of childbearing potential.
Lactation: Radiolabeled tafluprost and/or its metabolites were excreted in the milk of lactating rats. It is not known whether the drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, use caution when ZIOPTAN is given to a nursing woman.
Not recommended in pediatric patients because of potential safety concerns related to increased pigmentation following long-term chronic use.